These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35422015)

  • 1. The partial µ-opioid agonist buprenorphine in autism spectrum disorder: a case report.
    Skoglund C; Leknes S; Heilig M
    J Med Case Rep; 2022 Apr; 16(1):152. PubMed ID: 35422015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The treatment of autism with low-dose phenytoin: a case report.
    Bird PD
    J Med Case Rep; 2015 Jan; 9():8. PubMed ID: 25592685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The problem of pain: Additive analgesic effect of tramadol and buprenorphine in a patient with opioid use disorder.
    Montalvo C; Genovese N; Renner J
    Subst Abus; 2019; 40(2):136-139. PubMed ID: 30835647
    [No Abstract]   [Full Text] [Related]  

  • 4. Challenging Case: Leveraging Community Partnerships to Address Barriers to Care for Students with Autism.
    Cerda N; Brinster M; Turner C; Shahidullah JD; Augustyn M
    J Dev Behav Pediatr; 2023 Apr; 44(3):e239-e241. PubMed ID: 36716769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autism Spectrum Disorder and Mental Health Comorbidity Leading to Prolonged Inpatient Admission.
    Gupta S; Caskey A; Soares N; Augustyn M
    J Dev Behav Pediatr; 2018; 39(6):523-525. PubMed ID: 30045160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of a serious autistic disorder in a child with Naltrexone in an oral suspension form].
    Desjardins S; Doyen C; Contejean Y; Kaye K; Paubel P
    Encephale; 2009 Apr; 35(2):168-72. PubMed ID: 19393386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Functioning Autism, Severe Anxiety, and Bullying in a 26 Year Old.
    Fogler JM; Stein D; Barbaresi WJ; Bridgemohan C; Steinbauer-Schütz A; Dirmhirn A; Holzinger D; Radesky J; Fellinger J
    J Dev Behav Pediatr; 2019 May; 40(4):312-314. PubMed ID: 31008802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apraxia, Autism, Attention-Deficit Hyperactivity Disorder: Do We Have a New Spectrum?
    Schumacher J; Strand KE; Augustyn M
    J Dev Behav Pediatr; 2017; 38 Suppl 1():S35-S37. PubMed ID: 28141716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
    Robbins M; Haroz R; Mazzarelli A; Clements D; Jones CW; Salzman M
    J Subst Abuse Treat; 2021 Nov; 130():108405. PubMed ID: 34118697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apraxia, autism, attention-deficit hyperactivity disorder: do we have a new spectrum?
    Schumacher J; Strand KE; Augustyn M
    J Dev Behav Pediatr; 2015; 36(2):124-6. PubMed ID: 25650955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attention and written expression in school-age, high-functioning children with autism spectrum disorders.
    Zajic MC; McIntyre N; Swain-Lerro L; Novotny S; Oswald T; Mundy P
    Autism; 2018 Apr; 22(3):245-258. PubMed ID: 27940570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive, social, and behavioral manifestations of the co-occurrence of autism spectrum disorder and attention-deficit/hyperactivity disorder: A systematic review.
    Rosello R; Martinez-Raga J; Mira A; Pastor JC; Solmi M; Cortese S
    Autism; 2022 May; 26(4):743-760. PubMed ID: 34961363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Atomoxetine in Individuals with Attention-Deficit/Hyperactivity Disorder and Low-Functioning Autism Spectrum Disorder.
    Kilincaslan A; Mutluer TD; Pasabeyoglu B; Tutkunkardas MD; Mukaddes NM
    J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):798-806. PubMed ID: 27228116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weeding Out the Justification for Marijuana Treatment in Patients with Developmental and Behavioral Conditions.
    Nelson T; Liu YH; Bagot KS; Stein MT
    J Dev Behav Pediatr; 2017; 38(6):446-448. PubMed ID: 28622159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medications for attention-deficit/hyperactivity disorder in individuals with or without coexisting autism spectrum disorder: analysis of data from the Swedish prescribed drug register.
    Johansson V; Sandin S; Chang Z; Taylor MJ; Lichtenstein P; D'Onofrio BM; Larsson H; Hellner C; Halldner L
    J Neurodev Disord; 2020 Dec; 12(1):44. PubMed ID: 33357227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating opioid use disorder with rapid micro induction technique of sublingual buprenorphine/naloxone in an outpatient setting-a case report.
    Martell JP; Konakanchi JS; Sethi R
    J Addict Dis; 2022; 40(3):439-443. PubMed ID: 35072589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic Uncertainty in a Complex Young Man: Autism Versus Psychosis.
    Fogler J; Kuhn J; Prock L; Radesky J; Gonzalez-Heydrich J
    J Dev Behav Pediatr; 2019 Jan; 40(1):72-74. PubMed ID: 30601773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attached to a diagnosis: the quandary of social deficits and reactive attachment disorder.
    Phelps R; Eisert D; Schulz S; Augustyn M
    J Dev Behav Pediatr; 2012 Jan; 33(1):84-6. PubMed ID: 22218019
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.